UMMS Affiliation

School of Medicine

Publication Date


Document Type



Dermatology | Hemic and Immune Systems | Heterocyclic Compounds | Neoplasms | Pharmaceutical Preparations | Skin and Connective Tissue Diseases | Therapeutics


Imiquimod is a topical immunomodulator used for the treatment of viral warts and superficial basal cell carcinoma and as an emerging therapy for lentigo maligna and cutaneous melanoma metastases. Vitiligo-like depigmentation has been described as a local adverse effect of topical imiquimod therapy for melanoma1 and at distant sites in patients treated with combination topical monobenzone-imiquimod for metastatic melanoma.2 We present a case in which topical imiquimod resulted in both the resolution of in-transit metastatic melanoma and the depigmentation of local and regional skin, suggesting a regional lymphatic effect of this localized topical treatment.


CT, computed tomography, depigmentation, imiquimod, in-transit metastases, melanoma, vitiligo

Rights and Permissions

This is an open access article under the CC BY-NC-ND license (

DOI of Published Version



JAAD Case Rep. 2019 Apr 29;5(5):427-429. doi: 10.1016/j.jdcr.2019.03.015. eCollection 2019 May. Link to article on publisher's site

Journal/Book/Conference Title

JAAD case reports

Related Resources

Link to Article in PubMed

PubMed ID


Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.